Welcome to the Roche Virtual Neurology Investor Event Conference!
Company Participants
Bruno Eschli – Investor Relations
Azad Bonni – Senior Vice President and Global Head-Neuroscience and Rare Diseases-pRED
Luka Kulic – Therapeutic Area Leader-Dementia and Expert Medical Director-Neuroscience and Rare Diseases-pRED
Margherita Carboni – Indication Lead, Neurology and Clinical Development Lead-Neurology, Endocrinology and OBGYN-Roche Diagnostics
Hanno Svoboda – Head-Portfolio Development and Neuroscience and Rare Diseases
Conference Call Participants
Richard Parkes – BNP Paribas
Sachin Jain – Bank of America
Colin White – UBS
David Evans – Kepler
Luisa Hector – Berenberg
Richard Vosser – JPMorgan
Rajesh Kumar – HSBC
Colin White – UBS
Bruno Eschli [Call Starts Abruptly] Thanks Henrik, for the introduction. Can we please go to the agenda slide, please?
Going Beyond the Conference Call
The Roche Virtual Neurology Investor Event Conference promises to be an exciting and informative event for all attendees. With a lineup of top industry experts and key players in the field of neuroscience and rare diseases, participants can expect to gain valuable insights into the latest developments and upcoming projects in the neurology space.
From discussions on therapeutic advancements in dementia to breakthroughs in clinical development for neurology, this conference is set to provide a comprehensive overview of Roche’s initiatives and strategies for the future.
How Will This Affect Me?
As an investor or individual interested in the healthcare industry, attending the Roche Virtual Neurology Investor Event Conference can provide valuable knowledge and insights into the company’s current and future direction in the field of neurology. This event may offer potential investment opportunities or help guide decision-making processes related to healthcare investments.
How Will This Affect the World?
The outcomes and discussions emerging from the Roche Virtual Neurology Investor Event Conference have the potential to impact the broader healthcare landscape. New advancements and innovations in neurology and rare diseases could lead to improved treatment options for patients globally, ultimately contributing to the advancement of healthcare on a global scale.
Conclusion
Overall, the Roche Virtual Neurology Investor Event Conference is set to be an enlightening and engaging event that promises to deliver valuable insights into the future of neurology and rare diseases. With a lineup of esteemed speakers and industry experts, attendees can look forward to gaining a deeper understanding of Roche’s initiatives and their potential impact on both individuals and the world at large.
